Regulatory clearance from the U.S. Food and Drug Administration now extends to a once-daily autoinjector formulation of ZILBRYSQ, broadening how adults diagnosed with a particular type of myasthenia gravis can administer the therapy. Taken once daily, zilucoplan — sold under the brand name ZILBRYSQ — targets adults living with generalized myasthenia gravis whose bloodwork confirms the presence of acetylcholine receptor antibodies.
Administered beneath the skin, the device handles drug delivery through a route that already has an established place in the treatment landscape alongside the prefilled syringe.
Logged under an Oct. 15, 2026, date in the FDA's public drug database, the SUPPL-15 entry carries a classification of "Efficacy-New Indication," yet neither an approval letter nor a revised label accompanies the record, leaving the full scope of that supplement's intended use unspecified. Regulatory clearance for the product reached UCB on 16 October, with the company moving promptly to share the news.
Two findings drawn from a pair of studies appeared in summary form within a Neurology abstract. Fourteen healthy volunteers took part in a Phase 1 crossover trial, and delivery via autoinjector proved bioequivalent to administration by syringe. Thirty-one adults living with gMG were enrolled in a distinct Phase 3b trial.
Among the 449 times the treatment was administered, 448 resulted in a fully delivered dose — a completion rate of 99.8%, with the 95% confidence interval spanning from 98.8% up to 100%. By the fourteenth day of the study, participants rated self-injection at a median of 8.9 out of a possible 10 points for satisfaction. Of the seven individuals who took part, each one who experienced a treatment-related side effect described it as minor and not medically worrisome.
In a human-factors study of 100 participants — drawn from patients, caregivers, and healthcare professionals — nine out of ten were able to operate the autoinjector and deliver an injection on their first try, without any prior training, according to UCB.
Regulatory clearance for ZILBRYSQ among adults living with AChR-positive gMG came from the FDA during 2023. Meningococcal infection risk is listed in the drug's official labelling, which also specifies that vaccination is to be completed no fewer than two weeks before a patient begins treatment. In situations where a delay in care is not an option, healthcare providers are advised to administer antibacterial prophylaxis and arrange vaccination at the earliest opportunity.
The opening quarter of 2027 is when UCB anticipates the product becoming available to consumers in the U.S. market. No pricing details or reimbursement terms have been put forward by the firm.
